StockData
Kazia Therapeutics Ltd logo

Kazia Therapeutics Ltd (KZIA) stock

KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Nov 17, 2026Score 1/30
$5.49+0.18 (+3.39%)

Close on Nov 18, 2026Market cap $8.89MP/E –Yield –

Kazia Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Kazia Therapeutics's price to sales ratio was 282.0× on Nov 11, 2026, against 284.4× a year earlier. Over the last 4 years it ranged from 1.3× to 495.4×, with a median of 151.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026282.0×+12.4
2025Dec 31, 2025269.6×+266.3
2024Dec 31, 20243.3×+1.5
2022Aug 31, 20221.7×−7.3
2021Dec 31, 20219.0×−131.8
2019Aug 30, 2019140.7×+0.5
2018Dec 31, 2018140.2×−260.6
2017Aug 31, 2017400.8×–

More Kazia Therapeutics figures

See a number that looks wrong?